Related Experiment Video
Updated: Jul 20, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Hormone replacement therapy and glucose metabolism.
R J Triusu1, C C Cowie, M I Harris
1Social and Scientific Systems, Inc., Bethesda, Maryland, USA.
Obstetrics and Gynecology
|October 24, 2000
Summary
Hormone replacement therapy (HRT) use in women is increasing. Current HRT users showed lower basal glucose but higher post-challenge glucose levels, suggesting no adverse effect on overall glucose metabolism.
Area of Science:
- Endocrinology
- Metabolic Health
- Women's Health
Background:
- Hormone replacement therapy (HRT) is widely used by postmenopausal women.
- The impact of HRT on glucose metabolism, particularly in women with and without diabetes, requires further investigation.
Purpose of the Study:
- To investigate the association between hormone replacement therapy (HRT) use and glucose metabolism markers.
- To compare glucose metabolism in current, past, and never users of HRT.
Main Methods:
- Utilized cross-sectional data from the third National Health and Nutrition Examination Survey (NHANES III, 1988-1994).
- Analyzed hemoglobin A(1c), fasting and 2-hour glucose, and fasting insulin and C-peptide levels.
- Compared measures among HRT users and non-users, adjusting for confounders.
Main Results:
- Current HRT users exhibited lower hemoglobin A(1c) and fasting glucose but higher 2-hour glucose levels compared to never/past users.
- Adjusted analyses revealed a 0.1% lower A(1c), 3 mg/dL lower fasting glucose, and 15 mg/dL higher 2-hour glucose in current HRT users.
- No significant association was found between HRT use and fasting insulin or C-peptide levels.
Conclusions:
- HRT use appears to have no adverse effects on basal glucose metabolism.
- HRT use is associated with slightly elevated post-challenge glucose levels.
- The prevalence of HRT use among diabetic women is lower than in non-diabetic women but is increasing.
More Related Videos
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Related Concept Videos
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...